BioLineRx Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
BLRX
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 14.36M 53.34M | Sales 2025 * | 27.77M 103M | Capitalization | 54.6M 203M |
---|---|---|---|---|---|
Net income 2024 * | -47M -175M | Net income 2025 * | -36M -134M | EV / Sales 2024 * | 3.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.97 x |
P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |